Document:

EX-10.2

 Exhibit 10.2 

REGISTRATION RIGHTS AGREEMENT 

This Registration Rights Agreement (this “Agreement”) is made as of May 1, 2014, by and between Synageva BioPharma
Corp., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein,
capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1. 
 RECITALS 

WHEREAS, the Company and the Investors wish to provide for certain arrangements with respect to the registration of the Registrable
Securities (as defined below) by the Company under the Securities Act; and 
 WHEREAS, the Investors hereby waive, as a condition to
the Company’s execution and delivery of this Agreement, any and all registration rights attributable to the Investors pursuant to that certain Amended and Restated Information and Registration Rights Agreement, dated as of April 1, 2009,
among the Company and the investors named on Schedule 1.1 thereto (as amended, amended and restated or otherwise modified from time to time, the “Investor Rights Agreement”). 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, and other consideration, the receipt and
adequacy of which are hereby acknowledged, the parties hereto agree as follows: 
 Section 1 

Definitions 
 1.1.
Certain Definitions. In addition to the terms defined elsewhere in this Agreement, as used in this Agreement, the following terms have the respective meanings set forth below: 

(a) “Board” shall mean the Board of Directors of the Company. 

(b) “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the
Securities Act. 
 (c) “Common Stock” shall mean the common stock of the Company, par value $0.001 per share. 

(d) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and
the rules and regulations thereunder, all as the same shall be in effect from time to time. 
 (e) “Other Selling
Stockholders” shall mean persons other than the Investors who are from time to time entitled to include their Other Shares in certain registrations hereunder. 

 (f) “Other Shares” shall mean shares of Common Stock, other than Registrable
Securities (as defined below), with respect to which registration rights have been granted by the Company from time to time. 
 (g)
“Person” shall mean any individual, partnership, corporation, company, association, trust, joint venture, limited liability company, unincorporated organization, entity or division, or any government, governmental department or
agency or political subdivision thereof. 
 (h) “Registrable Securities” shall mean the shares of Common Stock or any other
securities (whether equity, debt or otherwise) of the Company that are held at the time of a demand pursuant to Section 2.1(a) by any of the Investors. 

(i) The terms “register,” “registered” and “registration” shall refer to a registration
effected by preparing and filing a Registration Statement in compliance with the Securities Act, and such Registration Statement becoming effective under the Securities Act. 

(j) “Registration Expenses” shall mean all expenses incurred by the Company in effecting any registration pursuant to this
Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company and up to Fifty-Thousand Dollars ($50,0000) of reasonable legal expenses of
one special counsel for Investors (if different from the Company’s counsel and if such counsel is reasonably approved by the Company) per underwritten public offering, blue sky fees and expenses, and expenses of any regular or special audits
incident to or required by any such registration, but shall not include Selling Expenses. 
 (k) “Registration Statement”
means any registration statement of the Company filed with, or to be filed with, the SEC under the Securities Act, including the related prospectus, amendments and supplements to such registration statement, including pre- and post-effective
amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws other than a registration statement (and related Prospectus) filed on Form S-4 or
Form S-8 or any successor forms thereto. 
 (l) “Rule 144” shall mean Rule 144 as promulgated by the Commission
under the Securities Act, as such rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

(m) “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar successor federal statute and the
rules and regulations thereunder, all as the same shall be in effect from time to time. 
 (n) “Selling Expenses” shall
mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities, the fees and expenses of any legal counsel and any other advisors any of the Investors engage and all similar fees and commissions relating to
the Investors’ disposition of the Registrable Securities. 

  
 2 

 Section 2 

Resale Registration Rights 

2.1. Resale Registration Rights. 

(a) Following demand by any Investor, the Company shall file with the Commission, as promptly as reasonably practicable, and in any event
within thirty (30) days of such demand, a Registration Statement on Form S-3 covering the resale of the Registrable Securities by the Investors submitting such demand (the “Resale Registration Shelf”). Such Resale Registration
Shelf shall include a “final” prospectus, including the information required by Item 507 of Regulation S-K of the Securities Act, as provided by the Investors. Notwithstanding the foregoing, before filing the Resale Registration
Shelf, the Company shall furnish to the Investors a copy of the Resale Registration Shelf and afford the Investors an opportunity to review and comment on the Resale Registration Shelf. The Company’s obligation pursuant to this
Section 2.1(a) is conditioned upon the Investors providing the information contemplated in Section 2.7. 
 (b) The
Company shall use its reasonable best efforts to cause the Resale Registration Shelf and related prospectuses to become effective as promptly as practicable after filing. The Company shall use its reasonable best efforts to cause such Registration
Statement to remain effective under the Securities Act until all Registrable Securities covered by the Resale Registration Shelf have been sold or may be sold freely without limitations or restrictions as to volume or manner of sale pursuant to Rule
144. The Company shall promptly, and within two (2) Business Days after the Company confirms effectiveness of the Resale Registration Shelf with the Commission, notify the Investors of the effectiveness of the Resale Registration Shelf. 

(c) Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to effect, or to take any action to effect,
a registration pursuant to Section 2.1(a): 
 (i) if the Company has and maintains an effective Registration Statement on Form
S-3 (including, without limitation, the Company’s current Registration Statement on Form S-3, filed on January 3, 2013 (File No. 333-185856)) that provides for the resale of an unlimited number of securities by selling stockholders
(the “Company Registration Shelf”); or 
 (ii) during the period forty-five (45) days prior to the Company’s
good faith estimate of the date of filing of a Company Registration Shelf. 
 (d) The Company shall file with the Commission, as promptly as
practicable, and in any event within ten (10) business days of this Agreement, a “final” prospectus to its Company Registration Shelf covering the resale of the Registrable Securities by the Investors (the
“Prospectus”). The Prospectus shall include the information required under Item 507 of Regulation S-K of the Securities Act, which information shall be provided by the Investors. Notwithstanding the foregoing, before filing the
Prospectus, the Company shall furnish to the Investors a copy of the Prospectus and afford the Investors an opportunity to review and comment on the Prospectus. 

  
 3 

 (e) Deferral and Suspension. At any time after being obligated to file a Resale
Registration Shelf or after any Resale Registration Shelf has become effective, the Company may defer the filing of or suspend the use of any such Resale Registration Shelf, upon giving written notice of such action to the Investors with a
certificate signed by the President of the Company stating that in the good faith judgment of the Board, the filing or use of a Registration Statement covering the Registrable Securities would be seriously detrimental to the Company or its
stockholders at such time and that the Board concludes, as a result, that it is in the best interests of the Company or its stockholders to defer the filing or suspend the use of such Resale Registration Shelf at such time. The Company shall have
the right to defer the filing of or suspend the use of such Resale Registration Shelf for a period of not more than one hundred twenty (120) days from the date the Company notifies the Investors of such deferral or suspension; provided that the
Company shall not exercise the right contained in this Section 2.1(d) more than once in any twelve month period. In the case of the suspension of use of any effective Resale Registration Shelf, the Investors, immediately upon receipt of
notice thereof from the Company, shall discontinue any sales of Registrable Securities pursuant to such Resale Registration Shelf until advised in writing by the Company that the use of such Resale Registration Shelf may be resumed. In the case of a
deferred Resale Registration Shelf, the Company shall provide prompt written notice to the Investors of (i) the Company’s decision to file or seek effectiveness of the Resale Registration Shelf following such deferral and (ii) the
effectiveness of such Resale Registration Shelf. 
 (f) Other Shares. Subject to Section 2.2(e) below, any Resale
Registration Shelf may include Other Shares, and may include securities of the Company being sold for the account of the Company; provided such Other Shares are excluded first from such Registration Statement in order to comply with any
applicable laws or request from any Government Entity, Nasdaq or any applicable listing agency. 
 2.2. Sales and Underwritten Offerings
of the Registrable Securities. 
 (a) Notwithstanding any provision contained herein to the contrary, the Investors, collectively,
shall, subject to the limitations set forth in this Section 2.2, be permitted one (1) underwritten public offering per calendar year to the effect the sale or distribution of Registrable Securities. 

(b) If the Investors intend to effect an underwritten public offering pursuant to the Resale Registration Shelf or the Company Registration
Shelf to sell or otherwise distribute Registrable Securities, they shall so advise the Company and provide as much notice to the Company as reasonably practicable (and in any event not less than ten (10) business days prior to the
Investors’ request that the Company file a prospectus supplement to a Resale Registration Shelf or Company Registration Shelf). 
 (c)
In connection with any offering initiated by the Investors involving an underwriting of shares of Common Stock, the Investors shall be entitled to select the underwriter or underwriters for such offering, subject to the consent of the Company, such
consent not to be unreasonably withheld, conditioned or delayed. 

  
 4 

 (d) In connection with any offering initiated by the Investors involving an underwriting of
shares of Common Stock, the Company shall not be required to include any of the Registrable Securities in such underwriting unless the Investors (i) enter into an underwriting agreement in customary form with such underwriter or underwriters,
(ii) accept customary terms in such underwriting agreement with regard to representations and warranties relating to ownership of the Registrable Securities and authority and power to enter into such underwriting agreement and
(iii) complete and execute all questionnaires, powers of attorney, custody agreements, indemnities and other documents as may be requested by such underwriter or underwriters. 

(e) If the total amount of securities to be sold in any offering initiated by the Investors involving an underwriting of shares of Common
Stock exceeds the amount that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including
Registrable Securities and securities of Other Selling Stockholders (subject in each case to the cutback provisions set forth in this Section 2.2(e)), that the underwriters and the Company determine in their sole discretion shall not
jeopardize the success of the offering. If the underwritten public offering has been requested pursuant to Section 2.2(a) hereof, the number of shares that are entitled to be included in the registration and underwriting shall be
allocated in the following manner: (a) first, securities of Other Selling Stockholders requested to be included in such registration shall be excluded, (b) second, shares of Company equity securities that the Company desires
to include in such registration shall be excluded and (c) third, Registrable Securities requested to be included in such registration by the Investors shall be excluded. If the underwritten public offering has been requested
contemporaneously with a request from the Holders under the Investor Rights Agreement, the number of shares that are entitled to be included in the registration and underwriting shall be allocated in the following manner: (a) first, the
shares held by officers or directors of the Company shall be excluded, (b) second, shares that are not Registrable Securities, as defined in this Agreement or the Investor Rights Agreement shall be excluded, (c) third, shares
of Company equity securities that the Company desires to include in such registration shall be excluded, and (d) fourth, Registrable Securities, as defined in this Agreement or the Investor Rights Agreement, requested to be included in
such registration by the Investors pursuant to this Agreement and the Holders pursuant to the Investor Rights Agreement shall be excluded in proportion to the respective amounts requested to be included. To facilitate the allocation of shares in
accordance with the above provisions, the Company or the underwriters may round down the number of shares allocated to any selling stockholder (including the Investors) to the nearest 100 shares. 

2.3. Expenses of Registration. All Registration Expenses incurred in connection with registrations pursuant to this Agreement
shall be borne by the Company. All Selling Expenses relating to securities registered on behalf of the Investors shall be borne by the Investors. 

2.4. Registration Procedures. In the case of each registration of Registrable Securities effected by the Company pursuant to
Section 2.1 (including pursuant to Section 2.1(c)(i)) hereof, the Company shall keep the Investors advised as to the initiation of each such registration and as to the status thereof. The Company shall use its reasonable best
efforts, within the limits set forth in this Section 2.4, to: 
 (a) prepare and file with the Commission such amendments and
supplements to such Registration Statement and the prospectuses used in connection with such Registration Statement as may be necessary to keep such Registration Statement effective and current and comply with the provisions of the Securities Act
with respect to the disposition of all securities covered by such Registration Statement; 

  
 5 

 (b) furnish to the Investors such numbers of copies of a prospectus, including preliminary
prospectuses, in conformity with the requirements of the Securities Act, and such other documents as the Investors may reasonably request in order to facilitate the disposition of Registrable Securities; 

(c) use its reasonable best efforts to register and qualify the securities covered by such Registration Statement under such other securities
or blue sky laws of such jurisdictions as shall be reasonably requested by the Investors, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions; 
 (d) in the event of any underwritten public offering, enter into and perform its
obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering and take such other usual and customary action as the Investors may request in order to facilitate the disposition of such
Registrable Securities; 
 (e) notify the Investors at any time when a prospectus relating to a Registration Statement covering any
Registrable Securities is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact
or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company shall use its reasonable best efforts to amend or supplement such
prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the
circumstances then existing; 
 (f) provide a transfer agent and registrar for all Registrable Securities registered pursuant to such
Registration Statement and, if required, a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(g) if requested by an Investor, cause the Company’s transfer agent to remove any restrictive legend from any Registrable Securities
being transferred by an Investor, within two (2) business days of such request; 
 (h) cause to be furnished, at the request of the
Investors, on the date that Registrable Securities are delivered to underwriters for sale in connection with an underwritten offering pursuant to this Agreement, (i) an opinion, dated such date, of the counsel representing the Company for the
purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, and (ii) a letter or letters from the independent certified public accountants of
the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters; and 

  
 6 

 (i) cause all such Registrable Securities included in a Registration Statement pursuant to this
Agreement to be listed on each securities exchange or other securities trading markets or which Common Stock is then listed. 
 2.5. The
Investors Obligations. 
 (a) Discontinuance of Distribution. The Investors agree that, upon receipt of any notice from the
Company of the occurrence of any event of the kind described in Section 2.4(e) hereof, the Investors shall immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable
Securities until the Investors’ receipt of the copies of the supplemented or amended prospectus contemplated by Section 2.4(e) hereof or receipt of notice that no supplement or amendment is required and that the Investors’
disposition of the Registrable Securities may be resumed. The Company may provide appropriate stop orders to enforce the provisions of this Section 2.5(a). 

(b) Compliance with Prospectus Delivery Requirements. The Investors covenant and agree that they shall comply with the prospectus
delivery requirements of the Securities Act as applicable to them or an exemption therefrom in connection with sales of Registrable Securities pursuant to any Registration Statement filed by the Company pursuant to this Agreement. 

(c) Notification of Sale of Registrable Securities. The Investors covenant and agree that they shall notify the Company following the
sale of Registrable Securities to a third party as promptly as reasonably practicable, and in any event within thirty (30) days, following the sale of such Registrable Securities. 

2.6. Indemnification. 

(a) To the extent permitted by law, the Company shall indemnify the Investors, and, as applicable, their officers, directors, and constituent
partners, legal counsel for each Investor and each Person controlling the Investors, with respect to which registration, related qualification, or related compliance of Registrable Securities has been effected pursuant to this Agreement, and each
underwriter, if any, and each Person who controls any underwriter within the meaning of the Securities Act against all claims, losses, damages, or liabilities (or actions in respect thereof) to the extent such claims, losses, damages, or liabilities
arise out of or are based upon (i) any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such registration,
qualification, or compliance, or (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation
by the Company of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law applicable to the Company and relating to action or
inaction required of the Company in connection with any such registration, qualification, or compliance; and the Company shall pay as incurred to the 

  
 7 

 
Investors, each such underwriter, and each Person who controls the Investors or underwriter, any legal and any other expenses reasonably incurred in connection with investigating or defending any
such claim, loss, damage, liability, or action; provided, however, that the indemnity contained in this Section 2.6(a) shall not apply to amounts paid in settlement of any such claim, loss, damage, liability, or action if
settlement is effected without the consent of the Company (which consent shall not unreasonably be withheld); and provided, further, that the Company shall not be liable in any such case to the extent that any such claim, loss, damage, liability, or
expense arises out of or is based upon any untrue statement or omission contained in such prospectus or other document based upon written information furnished to the Company by the Investors, such underwriter, or such controlling Person and stated
to be for use therein. 
 (b) To the extent permitted by law, each Investor (severally and not jointly) shall, if Registrable Securities
held by such Investor are included for sale in the registration and related qualification and compliance effected pursuant to this Agreement, indemnify the Company, each of its directors, each officer of the Company who signs the applicable
Registration Statement, each legal counsel and each underwriter of the Company’s securities covered by such a Registration Statement, each Person who controls the Company or such underwriter within the meaning of the Securities Act against all
claims, losses, damages, and liabilities (or actions in respect thereof) arising out of or based upon (i) any untrue statement (or alleged untrue statement) of a material fact contained in any such Registration Statement, or related document,
or (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by such Investor of the
Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law applicable to such Investor and relating to action or inaction required of such
Investor in connection with any such registration and related qualification and compliance, and shall pay as incurred to such persons, any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim,
loss, damage, liability, or action, in each case only to the extent that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in (and such violation pertains to) such Registration Statement or related
document in reliance upon and in conformity with written information furnished to the Company by such Investor and stated to be specifically for use therein; provided, however, that the indemnity contained in this Section 2.6(b) shall
not apply to amounts paid in settlement of any such claim, loss, damage, liability, or action if settlement is effected without the consent of such Investor (which consent shall not unreasonably be withheld); provided, further, that such
Investor’s liability under this Section 2.6(b) (when combined with any amounts such Investor is liable for under Section 2.6(d)) shall not exceed such Investor’s net proceeds from the offering of securities made in
connection with such registration. 
 (c) Promptly after receipt by an indemnified party under this Section 2.6 of notice of the
commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this Section 2.6, notify the indemnifying party in writing of the commencement thereof and
generally summarize such action. The indemnifying party shall have the right to participate in and to assume the defense of such claim; provided, however, that the indemnifying party shall be entitled to select counsel for the defense
of such claim with the approval of any parties entitled to indemnification, which 

  
 8 

 
approval shall not be unreasonably withheld; provided further, however, that if either party reasonably determines that there may be a conflict between the position of the Company and the
Investors in conducting the defense of such action, suit, or proceeding by reason of recognized claims for indemnity under this Section 2.6, then counsel for such party shall be entitled to conduct the defense to the extent reasonably
determined by such counsel to be necessary to protect the interest of such party. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to defend such
action, shall relieve such indemnifying party, to the extent so prejudiced, of any liability to the indemnified party under this Section 2.6, but the omission so to notify the indemnifying party shall not relieve such party of any
liability that such party may have to any indemnified party otherwise than under this Section 2.6. 
 (d) If the indemnification
provided for in this Section 2.6 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in
lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the
relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant
equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a
material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. In no
event, however, shall (i) any amount due for contribution hereunder be in excess of the amount that would otherwise be due under Section 2.6(a) or Section 2.6(b), as applicable, based on the limitations of such
provisions and (ii) a Person guilty of fraudulent misrepresentation (within the meaning of the Securities Act) be entitled to contribution from a Person who was not guilty of such fraudulent misrepresentation. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; provided, however, that the failure of the
underwriting agreement to provide for or address a matter provided for or addressed by the foregoing provisions shall not be a conflict between the underwriting agreement and the foregoing provisions. 

(f) The obligations of the Company and the Investors under this Section 2.6 shall survive the completion of any offering of
Registrable Securities in a Registration Statement under this Agreement or otherwise. 
 2.7. Information. The Investors shall
furnish to the Company such information regarding the Investors and the distribution proposed by the Investors as the Company may reasonably request and as shall be reasonably required in connection with any registration referred to in this
Agreement. The Investors agree to, as promptly as practicable (and in any 

  
 9 

 
event prior to any sales made pursuant to a prospectus), furnish to the Company all information required to be disclosed in order to make the information previously furnished to the Company by
the Investors not misleading. The Investors agree to keep confidential the receipt of any notice received pursuant to Section 2.4(e) and the contents thereof, except as required pursuant to applicable law. Notwithstanding anything to the
contrary herein, the Company shall be under no obligation to name the Investors in any Registration Statement if the Investors have not provided the information required by this Section 2.7 with respect to the Investors as a selling
securityholder in such Registration Statement or any related prospectus. 
 2.8. Rule 144 Requirements. With a view to making
available to the Investors the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the Commission that may at any time permit the Investors to sell Registrable Securities to the public without registration,
the Company agrees to use its reasonable best efforts to: 
 (a) make and keep public information available, as those terms are understood
and defined in Rule 144 under the Securities Act at all times after the date hereof; 
 (b) file with the Commission in a timely manner all
reports and other documents required of the Company under the Securities Act and the Exchange Act; 
 (c) prior to the filing of the
Registration Statement or any amendment thereto (whether pre-effective or post-effective), and prior to the filing of any prospectus or prospectus supplement related thereto, to provide the Investors with copies of all of the pages thereof (if any)
that reference the Investors; and 
 (d) furnish to any Investor, so long as the Investor owns any Registrable Securities, forthwith upon
request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company for an
offering of its securities to the general public), the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), (ii) a copy of the most recent annual or quarterly report of the Company and
such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested by an Investor in availing itself of any rule or regulation of the Commission which permits an Investor to sell any such
securities without registration. 
 2.9. Termination of Status as Registrable Securities. The Registrable Securities shall cease to
be Registrable Securities upon the earliest to occur of the following events: (i) such Registrable Securities have been sold pursuant to an effective Registration Statement; (ii) such Registrable Securities have been sold by the Investors
pursuant to Rule 144 (or other similar rule), provided, further, that each Registrable Security shall cease to be deemed a Registrable Security for so long as such Registrable Security may be resold by the Investors without limitations as to
volume or manner of sale pursuant to Rule 144; or (iii) ten (10) years after the date of this Agreement. 

  
 10 

 Section 3 

Miscellaneous 
 3.1.
Amendment. No amendment, alteration or modification of any of the provisions of this Agreement shall be binding unless made in writing and signed by each of the Company and the Investors 

3.2. Injunctive Relief. It is hereby agreed and acknowledged that it shall be impossible to measure in money the damages that would be
suffered if the parties fail to comply with any of the obligations herein imposed on them and that in the event of any such failure, an aggrieved Person shall be irreparably damaged and shall not have an adequate remedy at law. Any such Person
shall, therefore, be entitled (in addition to any other remedy to which it may be entitled in law or in equity) to injunctive relief, including, without limitation, specific performance, to enforce such obligations, and if any action should be
brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law. 

3.3. Notices. All notices required or permitted under this Agreement must be in writing and sent to the address or facsimile number
identified below. Notices must be given: (a) by personal delivery, with receipt acknowledged; (b) by facsimile followed by hard copy delivered by the methods under clause (c) or (d); (c) by prepaid certified or
registered mail, return receipt requested; or (d) by prepaid reputable overnight delivery service. Notices shall be effective upon receipt. Either party may change its notice address by providing the other party written notice of such change.
Notices shall be delivered as follows: 
  

			
	If to the Investors:	  	At such Investor’s address as set forth on Schedule A hereto
		
	If to the Company:	  	Synageva BioPharma Corp.
		  	Attention: Sanj K. Patel, Chief Executive Officer
		  	128 Spring Street
		  	Suite 520
		  	Lexington, MA 02421
		
	with a copy to:	  	Ropes & Gray LLP
		  	Attention: Paul Kinsella
		  	Prudential Tower
		  	800 Boylston Street
		  	Boston, MA 02199-3600
		  	Fax: (617) 235-0822

 3.4. Governing Law; Jurisdiction; Venue; Jury Trial. 

(a) This Agreement shall be governed by, and construed in accordance with, the law of the State of New York without giving effect to any
choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York. 

  
 11 

 (b) Each of the Company and the Investors irrevocably and unconditionally submits, for itself and
its property, to the nonexclusive jurisdiction of the courts of the State of New York sitting in the Borough of Manhattan, New York and of the United States District Court of the Southern District of New York, and any appellate court from any
thereof, in any action or proceeding arising out of or relating to this Agreement and the transactions contemplated herein, or for recognition or enforcement of any judgment, and each of the Company and the Investors irrevocably and unconditionally
agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York state court or, to the fullest extent permitted by applicable law, in such federal court. Each of the Company and the Investors hereto
agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 

(c) Each of the Company and the Investors irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any
objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement and the transactions contemplated herein in any court referred to in Section 3.4(b) hereof. Each
of the Company and the Investors hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 

(d) EACH OF THE COMPANY AND THE INVESTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE
TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH OF THE COMPANY AND THE INVESTORS
(A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES
THAT EACH OF THE COMPANY AND THE INVESTORS HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

3.5. Successors, Assigns and Transferees. Any and all rights, duties and obligations hereunder shall not be assigned, transferred,
delegated or sublicensed by any party hereto without the prior written consent of the other party; provided, however, that the Investors shall be entitled to transfer Registrable Securities to one or more of their affiliates and,
solely in connection therewith, may assign their rights hereunder in respect of such transferred Registrable Securities, in each case, so long as such Investor is not relieved of any liability or obligations hereunder, without the prior consent of
the Company. Any transfer or assignment made other than as provided in the first sentence of this Section 3.5 shall be null and void. Subject to the foregoing and except as otherwise provided herein, the provisions of this Agreement
shall inure to the benefit of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. 

  
 12 

 3.6. Entire Agreement. This Agreement, together with any exhibits hereto, constitute the
entire agreement between the parties relating to the subject matter hereof and all previous agreements or arrangements between the parties, written or oral, relating to the subject matter hereof are superseded. 

3.7. Waiver. No failure on the part of either party hereto to exercise any power, right, privilege or remedy under this Agreement, and
no delay on the part of either party hereto in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver thereof; and no single or partial exercise of any such power, right, privilege or remedy shall preclude
any other or further exercise thereof or of any other power, right, privilege or remedy. 
 3.8. Severability. If any part of this
Agreement is declared invalid or unenforceable by any court of competent jurisdiction, such declaration shall not affect the remainder of the Agreement and the invalidated provision shall be revised in a manner that shall render such provision valid
while preserving the parties’ original intent to the maximum extent possible. 
 3.9. Titles and Subtitles. The titles and
subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless otherwise provided, refer
to sections and paragraphs hereof and exhibits attached hereto. 
 3.10. Counterparts. This Agreement may be executed in any number
of counterparts, each of which shall be enforceable against the parties that execute such counterparts (including by facsimile or other electronic means), and all of which together shall constitute one instrument. 

3.11. Term and Termination. The Investors’ rights to demand the registration of the Registrable Securities under this Agreement
shall terminate automatically once all Registrable Securities cease to be Registrable Securities pursuant to the terms of Section 2.9 of this Agreement. 

[Remainder of Page Intentionally Left Blank; Signature Page Follows] 

  
 13 

 IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement effective
as of the day, month and year first above written. 
  

			
	SYNAGEVA BIOPHARMA CORP.
	a Delaware Corporation
		
	By:	 	 /s/ Sanj K. Patel

	Name:	 	Sanj K. Patel
	Title:	 	President and Chief Executive Officer

 [Signature Page to Registration Rights Agreement] 

 IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement effective
as of the day, month and year first above written. 
  

			
	14159, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to 14159, L.P., pursuant to authority granted to it by 14159 Capital, L.P., general partner to 14159, L.P., and not as the general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President
	
	667, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President
	
	BAKER BROS. INVESTMENTS II, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER BROS. INVESTMENTS II, L.P., pursuant to authority granted to it by Baker Bros. Capital, L.P., general partner to BAKER BROS. INVESTMENTS II, L.P., and not
as the general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President

 [Signature Page to Registration Rights Agreement] 

 
			
	BAKER BROTHERS LIFE SCIENCES, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to BAKER BROTHERS LIFE
SCIENCES, L.P., and not as the general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President
	
	BAKER BROS. INVESTMENTS, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER BROS. INVESTMENTS, L.P., pursuant to authority granted to it by Baker Bros. Capital, L.P., general partner to BAKER BROS. INVESTMENTS, L.P., and not as the
general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President
	
	BAKER/TISCH INVESTMENTS, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER/TISCH INVESTMENTS, L.P., pursuant to authority granted to it by Baker/Tisch Capital, L.P., general partner to BAKER/TISCH INVESTMENTS, L.P., and not as the
general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President

 [Signature Page to Registration Rights Agreement] 

 
			
	BAKER BIOTECH FUND II (A), L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER BIOTECH FUND II (A), L.P., pursuant to authority granted to it by Baker Biotech Capital II (A), L.P., general partner to BAKER BIOTECH FUND II (A), L.P.,
and not as the general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President

 [Signature Page to Registration Rights Agreement] 

 IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement effective
as of the day, month and year first above written. 
  

			
	THOMAS J. TISCH 1994 ISSUE TRUST
		
	By:	 	 /s/ Thomas J. Tisch

		 	Thomas J. Tisch
		 	Trustee
	
	THOMAS J. TISCH
	
	 /s/ Thomas J. Tisch

	
	THOMAS J. TISCH 1999 TRUST
		
	By:	 	 /s/ Thomas J. Tisch

		 	Thomas J. Tisch
		 	Trustee

 [Signature Page to Registration Rights Agreement]EX-10.3

 Exhibit 10.3 

Amendment to Amended and Restated Information and Registration Rights Agreement 

This Amendment to the Amended and Restated Information and Registration Rights Agreement (this “Amendment”) is made and
entered into as of May 1, 2014 by and among Synageva BioPharma Corp., a Delaware corporation (the “Company”) and the persons who are signatories to this Amendment (collectively, the “Investors”). Capitalized
terms used herein without definition shall have the meanings ascribed to them in the Amended and Restated Information and Registration Rights Agreement, dated as of April 1, 2009, between the Company and the Investors, as amended (the
“Agreement”). 
 WITNESSETH 

WHEREAS, Section 14 of the Agreement prohibits the Company from entering into any agreement with any holder or prospective holder
of securities of the Company that provides such holder with any information or Registration rights; and 
 WHEREAS, the Investors
agreed to amend the Agreement so that Section 14 of the Agreement would be deleted in its entirety to permit the Company to provide for such arrangements. 

NOW, THEREFORE, for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and
the Investors agree as follows: 
 1. Section 14 of the Agreement. Section 14 of the Agreement shall be deleted in its
entirety and amended to read as follows: 
 “[RESERVED.]” 

2. Miscellaneous Provisions. 

2.1 Effect of Amendment. In the event of any conflict or inconsistency between the terms of this Amendment and the terms of the
Agreement, the terms of this Amendment will control. Except to the extent expressly modified herein or in conflict with the terms of this Amendment, the terms of the Agreement shall remain in full force and effect. 

2.2 Counterparts. This Amendment may be executed in multiple counterparts, each of which shall be deemed an original but both of which
together shall constitute one and the same instrument. 
 2.3 No Amendment. No amendment, alteration or modification of any of the
provisions of this Amendment will be binding unless made in writing and signed by each of the parties hereto. 
 2.4 Entire
Agreement. This Amendment and the Agreement embody the entire agreement and understanding of the parties hereto in respect of the subject matter contained herein and therein. 

 2.5 Governing Law. This Amendment shall be governed by, and construed in accordance with,
the law of the State of California, excluding those laws that direct the application of the laws of another jurisdiction. 

  
 2 

 IN WITNESS WHEREOF, each of the undersigned has executed this Amendment as an agreement under
seal as of the date first above written. 
  

			
	SYNAGEVA BIOPHARMA CORP.
		
	By:	 	 /s/ Sanj K. Patel

	Name:	 	Sanj K. Patel
	Title:	 	President and Chief Executive Officer

 [Signature Page to Amendment to Rights Agreement] 

 
			
	14159, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to 14159, L.P., pursuant to authority granted to it by 14159 Capital, L.P., general partner to 14159, L.P., and not as the general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President
	
	667, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President
	
	BAKER BROS. INVESTMENTS II, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER BROS. INVESTMENTS II, L.P., pursuant to authority granted to it by Baker Bros. Capital, L.P., general partner to BAKER BROS. INVESTMENTS II, L.P., and not
as the general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President

 [Signature Page to Amendment to Rights Agreement] 

			
	BAKER BROTHERS LIFE SCIENCES, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to BAKER BROTHERS LIFE
SCIENCES, L.P., and not as the general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President
	
	BAKER BROS. INVESTMENTS, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER BROS. INVESTMENTS, L.P., pursuant to authority granted to it by Baker Bros. Capital, L.P., general partner to BAKER BROS. INVESTMENTS, L.P., and not as the
general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President
	
	BAKER/TISCH INVESTMENTS, L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER/TISCH INVESTMENTS, L.P., pursuant to authority granted to it by Baker/Tisch Capital, L.P., general partner to BAKER/TISCH INVESTMENTS, L.P., and not as the
general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President

 [Signature Page to Amendment to Rights Agreement] 

 
			
	BAKER BIOTECH FUND II (A), L.P.
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER BIOTECH FUND II (A), L.P., pursuant to authority granted to it by Baker Biotech Capital II (A), L.P., general partner to BAKER BIOTECH FUND II (A), L.P.,
and not as the general partner
		
	By:	 	 /s/ Scott L. Lessing

		 	Scott L. Lessing
		 	President

 [Signature Page to Amendment to Rights Agreement] 

 
			
	FBB ASSOCIATES
		
	By:	 	 /s/ Felix Baker, Ph.D.

		 	Felix Baker, Ph.D.
		 	General Partner

 [Signature Page to Amendment to Rights Agreement] 

 
			
	ANDREW H. TISCH
	
	 /s/ Andrew H. Tisch

	
	DANIEL R. TISCH
	
	 /s/ Daniel R. Tisch

	
	JAMES S. TISCH
	
	 /s/ James S. Tisch

	
	THOMAS J. TISCH 1994 ISSUE TRUST
		
	By:	 	 /s/ Thomas J. Tisch

	Name:	 	Thomas J. Tisch
	Title:	 	Trustee

 [Signature Page to Amendment to Rights Agreement] 

 
			
	THOMAS J. TISCH
	
	 /s/ Thomas J. Tisch

	
	THOMAS J. TISCH 1999 TRUST
		
	By:	 	 /s/ Thomas J. Tisch

	Name:	 	Thomas J. Tisch
	Title:	 	Trustee
	
	JT FAMILY PARTNERSHIP
		
	By:	 	 /s/ James S. Tisch

	Name:	 	James S. Tisch
	Title:	 	Manager
	
	SAMUEL A. TISCH
	
	 /s/ Samuel A. Tisch

 [Signature Page to Amendment to Rights Agreement] 

 
			
	BENJAMIN J. TISCH 2011 TRUST
		
	By:	 	 /s/ James S. Tisch

	Name:	 	James S. Tisch
	Title:	 	Trustee
	
	JESSICA S. TISCH 2011 TRUST
		
	By:	 	 /s/ James S. Tisch

	Name:	 	James S. Tisch
	Title:	 	Trustee
	
	JAMES S. TISCH 1999 TRUST
		
	By:	 	 /s/ James S. Tisch

	Name:	 	James S. Tisch
	Title:	 	Trustee
	
	ANDREW H. TISCH 1995 ISSUE TRUST #2
		
	By:	 	 /s/ Andrew H. Tisch

	Name:	 	Andrew H. Tisch
	Title:	 	Trustee

 [Signature Page to Amendment to Rights Agreement] 

 
			
	KAL FAMILY PARTNERSHIP
		
	By:	 	 /s/ Andrew H. Tisch

	Name:	 	Andrew H. Tisch
	Title:	 	Manager
	
	ALEXEANDER H. TISCH 2011 TRUST
		
	By:	 	 /s/ Andrew H. Tisch

	Name:	 	Andrew H. Tisch
	Title:	 	Trustee
	
	LACEY A. TISCH 2011 TRUST
		
	By:	 	 /s/ Andrew H. Tisch

	Name:	 	Andrew H. Tisch
	Title:	 	Trustee
	
	ANDREW H. TISCH 1999 TRUST
		
	By:	 	 /s/ Andrew H. Tisch

	Name:	 	Andrew H. Tisch
	Title:	 	Trustee

 [Signature Page to Amendment to Rights Agreement] 

 
			
	DANIEL R. TISCH 1999 ISSUE TRUST
		
	By:	 	/s/ Daniel R. Tisch
	Name:	 	Daniel R. Tisch
	Title:	 	Trustee
	
	DMA FAMILY PARTNERSHIP
		
	By:	 	/s/ Daniel R. Tisch
	Name:	 	Daniel R. Tisch
	Title:	 	Manager
	
	DANIEL R. TISCH 1999 TRUST
		
	By:	 	/s/ Daniel R. Tisch
	Name:	 	Daniel R. Tisch
	Title:	 	Trustee

 [Signature Page to Amendment to Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]